RU2009136669A - Лечение меланомы - Google Patents

Лечение меланомы Download PDF

Info

Publication number
RU2009136669A
RU2009136669A RU2009136669/15A RU2009136669A RU2009136669A RU 2009136669 A RU2009136669 A RU 2009136669A RU 2009136669/15 A RU2009136669/15 A RU 2009136669/15A RU 2009136669 A RU2009136669 A RU 2009136669A RU 2009136669 A RU2009136669 A RU 2009136669A
Authority
RU
Russia
Prior art keywords
melanoma
compound
group
tautomer
denotes
Prior art date
Application number
RU2009136669/15A
Other languages
English (en)
Russian (ru)
Inventor
Карла С. ХЕЙСИ (US)
Карла С. ХЕЙСИ
Пол ХОЛЛЕНБАХ (US)
Пол ХОЛЛЕНБАХ
Даниел МЕНЕЗЕШ (US)
Даниел МЕНЕЗЕШ
Нэнси ПРАЙЕР (US)
Нэнси ПРАЙЕР
Катерин РЕНДАЛ (US)
Катерин РЕНДАЛ
Марион ВИСМАНН (US)
Марион ВИСМАНН
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39500684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2009136669(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2009136669A publication Critical patent/RU2009136669A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2009136669/15A 2007-03-09 2008-03-07 Лечение меланомы RU2009136669A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89404607P 2007-03-09 2007-03-09
US60/894,046 2007-03-09
US91140607P 2007-04-12 2007-04-12
US60/911,406 2007-04-12

Publications (1)

Publication Number Publication Date
RU2009136669A true RU2009136669A (ru) 2011-04-20

Family

ID=39500684

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009136669/15A RU2009136669A (ru) 2007-03-09 2008-03-07 Лечение меланомы

Country Status (11)

Country Link
US (1) US20100086518A1 (enExample)
JP (1) JP2010520881A (enExample)
KR (1) KR20090119768A (enExample)
AU (1) AU2008226582B2 (enExample)
BR (1) BRPI0808714A2 (enExample)
CA (1) CA2679268A1 (enExample)
CL (1) CL2008000681A1 (enExample)
MX (1) MX2009009574A (enExample)
RU (1) RU2009136669A (enExample)
TW (1) TW200843766A (enExample)
WO (1) WO2008112509A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
TWI410418B (zh) 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
WO2010135534A2 (en) * 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
US8551479B2 (en) * 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
WO2016053249A1 (en) 2014-09-29 2016-04-07 Hewlett-Packard Development Company, L.P. Hinge assembly with compressible sleeve
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3103450A1 (en) 2015-06-12 2016-12-14 Friedrich-Alexander-Universität Erlangen-Nürnberg None-hydrophobic compounds for use in treating metastasis and/or cartilage defect
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
CN108610293B (zh) * 2018-06-15 2020-08-04 南京工业大学 一种采用微通道反应装置制备多韦替尼中间体的方法
WO2024097855A2 (en) * 2022-11-03 2024-05-10 University Of Florida Research Foundation, Incorporated Identification of small molecules that recruit and activate rnase l

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG148864A1 (en) * 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
JP4823914B2 (ja) * 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
EP2040738A1 (en) * 2006-07-13 2009-04-01 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
BRPI0715062A2 (pt) * 2006-07-28 2013-06-04 Novartis Ag mÉtodos para determinar uma resposta de um indivÍduo mamÍfero que tem cÉlulas de tumor de melanoma ao tratamento com um agente inibidor de melanoma, para avaliar a eficÁcia de um agente inibidor de melanoma para tratar melanoma em um indivÍduo mamÍfero que tem melanoma, para determinar se um paciente deve continuar a receber tratamento com um agente inibidor de melanoma e para identificar agente que tÊm utilidade no tratamento de melanoma

Also Published As

Publication number Publication date
CA2679268A1 (en) 2008-09-18
TW200843766A (en) 2008-11-16
CL2008000681A1 (es) 2008-10-24
JP2010520881A (ja) 2010-06-17
AU2008226582B2 (en) 2011-07-21
US20100086518A1 (en) 2010-04-08
MX2009009574A (es) 2009-09-16
BRPI0808714A2 (pt) 2014-08-12
WO2008112509A1 (en) 2008-09-18
AU2008226582A1 (en) 2008-09-18
KR20090119768A (ko) 2009-11-19

Similar Documents

Publication Publication Date Title
US6664264B2 (en) Thioether substituted imidazoquinolines
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
JP2019501195A5 (ja) 腫瘍を処置するための抗ｅｇｆｒ組み合わせ
RU2009120048A (ru) Способы и комбинированные средства для лечения болезни альцгеймера
JP2008526999A5 (enExample)
JP2006527776A5 (enExample)
RU2009102243A (ru) Производные камптотецина с противоопухолевой активностью
HUP0303432A2 (hu) Szubsztituált piridoindolok mint szerotonin agonisták és antagonisták, és a vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NZ596739A (en) Methods of treating proliferative diseases
AR030188A1 (es) Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
JP6240083B2 (ja) 樹状細胞癌ワクチンのための小分子エンハンサー
RU2016126656A (ru) Производные тетрагидроимидазопиридина в качестве модуляторов активновти tnf
JP2013528174A5 (enExample)
CN1360503A (zh) 用于治疗癌症的海鞘素743的组合物和用途
RU2010154173A (ru) Режим введения нитрокатехолов
RU2017119064A (ru) Композиции апилимода и способы его использования при лечениии меланомы
CN103327977A (zh) 恶液质的治疗或预防剂
JP2015522018A5 (enExample)
RU2005107589A (ru) Антидепрессанты-азагетероциклилметильные производные конденсированных с гетероциклами бензодиоксанов
RU2007143505A (ru) Производные ацетилена
RU2016127440A (ru) Производные тетрагидроимидазопиридина в качестве модуляторов активности tnf
RU2013130926A (ru) Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака
WO2003072049A3 (en) Induction of hair growth with vascular endothelial growth factor
RU2016110546A (ru) Комбинированная лекарственная терапия
US20100240595A1 (en) Improved Antitumoral Treatments

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20120618